SBIR/STTR Research Award

Bead-array for rapid risk-stratification in leukemia

Award identifier 7c9b55de503a2d92b00a556da42755c958bd672d715b3fdca7944250d78b0764Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$228,251

Program and phase

SBIR · Phase I

Award year

2005

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
AMBION DIAGNOSTICS, INC.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
PHS2005-2
Topic code
Not reported

Research abstract

DESCRIPTION (provided by applicant): Accurate differentiation of fusion transcripts derived from chromosome translocations is of critical importance for optimizing treatment strategies for leukemia. However, as the number of leukemia associated translocations is steadily increasing, single-tube, multiplex detection of multiple fusion gene transcripts becomes challenging. The overall goal of this proposal is to develop an assay system for rapid risk-stratification of chromosomal translocations in leukemia. The system combines multiplex RT-PCR with multiplex signal detection on fluorescent beads in a 96-well plate format. Clinical decision-making is based on the relative expression level of a specific fusion target to the internal or exogenous controls. The assay offers significant improvements in speed and cost over currently available assays and can be applied for a high-throughput risk-stratification in leukemia diagnostics. This assay is flexible to be easily adapted to other nucleic-based assays useful for cancer/diseases diagnostics. Specific aims for Phase I: (1) Develop a rapid single-tube assay for simultaneous identification of common chromosome translocations related to leukemia in a single tube (up to 21 translocations). (2) Develop a comprehensive control system for the clinical test of this assay. In Phase II we will adapt this assay into a robust, high-throughput clinic diagnostic kit for rapid risk stratification in leukemia. Our second aim for Phase II is to produce armored RNAs for exogenous control and all positive target controls using well-established in-house system and test the amplification and detection efficiency of these armored RNA controls. The use of armored RNA ensures the stability of our positive controls in the assay system.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.